AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
1. AbbVie reported Q2 2025 sales of $15.42 billion, beating expectations. 2. Adjusted earnings were $2.97, missing consensus of $3.23 per share. 3. Guggenheim raised revenue and EPS forecasts for 2025 due to strong product performance. 4. Analysts maintain 'Buy' ratings, increasing AbbVie's price targets. 5. Concerns about drug price pressures remain, but growth forecasts are positive.